Stockwatch: Fanfare For A Down Year
This article was originally published in Scrip
Executive Summary
The build-up to this year's annual JP Morgan Healthcare conference in San Francisco has been muted by recent events and portends a year that has started very differently from the last. This year's dramatic falls and suspended trading in mainland Chinese stock markets as well as commodity weakness have cast a deep shadow over the healthcare sector, the share prices of which cannot avoid an association with one of the worst stock market starts for many years.
You may also be interested in...
Stockwatch: Awkward Developments Pricking J.P. Morgan Bubble
The warm fuzzy feeling in life sciences in the week before the J.P. Morgan Healthcare Conference was rudely threatened by clinical trial results from Halozyme and Heron, and negative financial preannouncements from Heron and Teva.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.